Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors Abstract #2038

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Aim(s): Supplemental updated analysis was requested by regulatory authorities for registration purposes. Quality of life (QoL) was analysed with the same new cut-off date (30.07.2016) for time to clinically relevant deterioration (TTD) in health-related QoL (HRQoL).
Materials and methods: Overall survival (OS) and PFS were evaluated using Kaplan Meier Methodology. HRQoL analysis was based on EORTC QLQC-30 and G.I.NET-21 questionnaires, completed at baseline and every 12 weeks thereafter. TTD was defined as the time from randomization to the first QoL deterioration ≥10 points for each patient in the corresponding domain scale.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#1062 United Kingdom NET Patient Survey Quality of Life Results
Introduction: QoL is of paramount importance in patients diagnosed with cancer, this is especially true in patients with NETs since the median survival from diagnosis is 7 years.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Raj Srirajaskanthan
Keywords: Quality of life, NET
#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
Keywords: Lutathera, PRRT, NET
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#1825 The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study
Introduction: Neuroendocrine tumour (NET) patients experience poor health-related quality of life (HRQOL). Peptide receptor radionuclide therapy (PRRT) is a promising treatment option although its impact on HRQOL is not well understood.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dainik Patel
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.